#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Cognitive disorder Erdheim-Chester disease Polycythaemia vera Netherton's syndrome Ocular myasthenia Skin cancer Chronic cutaneous lupus erythematosus Dilated cardiomyopathy Giant cell tumour of tendon sheath Hyperphagia Synovial sarcoma recurrent Ehlers-Danlos syndrome Hepatic cirrhosis Plasma cell myeloma recurrent Acute myeloid leukaemia refractory More trials…

    Learn about Rare Diseases

    Lymphangioma – Trials in Disease Richter’s syndrome – Treatment Familial amyotrophic lateral sclerosis Piriformis syndrome – Basic Information Hereditary neuropathic amyloidosis – Life with Disease KBG syndrome – Trials in Disease Alveolar rhabdomyosarcoma – Basic Information Alport’s syndrome – Trials in Disease Chondrosarcoma metastatic – Treatment Splenic marginal zone lymphoma – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    RO7288817 Ecoo16 Amlitelimab Gemcitabine Potassium Iodide Bevacizumab Alxn2220 Altizide Alxn1850 R2R01 GOCATAMIG L-Acetylleucine Liraglutide IDROXIOLEIC ACID ZIRCONIUM (89ZR) GIRENTUXIMAB Naloxone Asciminib Hydrochloride F1245/05 Calcifediol Aluminium Oxide, Hydrated More therapies…

    Learn about Your Condition

    Carotid arteriosclerosis Naevoid melanoma Heart disease congenital Epidermolysis bullosa Bronchiolitis Agitation Oesophageal adenocarcinoma Prostate cancer metastatic Pyoderma gangrenosum Ankylosing spondylitis Infertility Systemic lupus erythematosus Lymphocytic leukaemia High-grade B-cell lymphoma Hyperoxaluria More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Plasma cell myeloma

  • Study Comparing Idecabtagene Vicleucel and Lenalidomide Maintenance Therapy for Adults with Newly Diagnosed Multiple Myeloma After Stem Cell Transplant

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Diphenhydramine Hydrochloride
    • Fludarabine Phosphate Ph. Eur.
    • Idecabtagene Vicleucel
    Austria Belgium Czechia Denmark France Germany +6

  • Study of Elranatamab for Treating Relapsed or Refractory Multiple Myeloma in Patients Previously Treated with Three Drug Classes

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Elranatamab
    Spain

  • Study on Human Normal Immunoglobulin to Prevent Early Infections in Patients with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Human Normal Immunoglobulin
    Denmark Estonia Norway

  • Study on the Safety and Effects of Forimtamig, Tocilizumab, and Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma

    Not recruiting

    1 1 1 1
    Investigated Drugs:
    • Forimtamig
    • Carfilzomib
    • Daratumumab
    Denmark France Germany Italy Spain

  • Study on Venetoclax, Carfilzomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Carfilzomib
    • Dexamethasone
    • Venetoclax
    Hungary Spain

  • Study of Daratumumab Injection for Patients with High-Risk Smoldering Multiple Myeloma

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Daratumumab
    Belgium Czechia Denmark France Germany Greece +7
Previous Page
1 … 21 22 23 24 25 … 27
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!